Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
American Journal of Clinical Oncology|December 1, 1991
Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot studyA S Spiers, J H Weens, J M Rowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
Pentostatin induces durable remissions in hairy cell leukemiaP A Cassileth, B Cheuvart, A S Spiers, et al.
The New England Journal of Medicine|April 2, 1987
Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin)A S Spiers, D Moore, P A Cassileth, et al.
British Medical Journal|January 25, 1975
Chronic granulocytic leukaemia: effect of elective splenectomy on the course of diseaseA S Spiers, A F Baikie, D A Galton, et al.
Lancet (London, England)|October 4, 1975
Splenectomy for complications of chronic granulocytic leukaemiaA S Spiers, A G Baikie, D A Galton, et al.
Lancet (London, England)|February 15, 1975
Granulocyte transfusions in treatment of infections in patients with acute leukaemia and aplastic anaemiaR M Lowenthal, L Grossman, J M Goldman, et al.
Cancer Treatment Reports|April 1, 1986
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot StudyK M Rowland, S G Taylor, A S Spiers, et al.
British Medical Journal|December 13, 1975
Acute lymphoblastic leukaemia: cyclical chemotherapy with three combinations of four drugs (COAP-POMP-CART regimen)A S Spiers, P D Roberts, G W Marsh, et al.
Scandinavian Journal of Haematology|January 1, 1985
T-cell chronic lymphocytic leukaemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2'-deoxycoformycin)A S Spiers, M P Davis, M Levine, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Pageof 10